Previous 10 | Next 10 |
BEDMINSTER, N.J., Oct. 14, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that it has initiated its Phase 2 EnACT clinical study, which will explore the use of MAT2203 for both induction and maintenanc...
BEDMINSTER, N.J., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MAT2203, Matinas’ proprietar...
BEDMINSTER, N.J., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that Jerome D. Jabbour, Chief Executive Officer, will present a company overview, as well as host investor meetings, at the 20...
BEDMINSTER, N.J., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that it has commenced pre-screening patients to determine eligibility for ENHANCE-IT, its Phase 2 head-to-head pharmacodynamic...
The following slide deck was published by Matinas BioPharma Holdings, Inc. in conjunction with this Read more ...
BEDMINSTER, N.J., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that Jerome D. Jabbour, Chief Executive Officer, will present a company overview, as well as host investor meetings, at the H.C...
Matinas BioPharma Holdings, Inc. (MTNB) Q2 2019 Earnings Conference Call August 13, 2019 08:00 ET Company Participants Jerry Jabbour - Chief Executive Officer Terry Ferguson - Chief Medical Officer Theresa Matkovits - Chief Development Officer Keith Kucinski - Chief Financial O...
Matinas Biopharma ( MTNB ) Q2 results : Revenues: $0.09M (unch). More news on: Matinas BioPharma Holdings, Inc., Healthcare stocks news, Earnings news and commentary, , Read more ...
Matinas Biopharma Holdings (NYSEMKT: MTNB ): Q2 GAAP EPS of -$0.03 beats by $0.01 . More news on: Matinas BioPharma Holdings, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
– MAT9001 program progressing ahead of schedule – – Additional head to head data vs. Vascepa® expected in 2020 – – NIH-funded Phase 1/2 EnACT trial of MAT2203 in cryptococcal meningitis to commence in Q4 2019 – – Management t...
News, Short Squeeze, Breakout and More Instantly...
Matinas Biopharma Holdings Inc. Company Name:
MTNB Stock Symbol:
NYSE Market:
BEDMINSTER, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focu...
BEDMINSTER, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that it will report fi...
BEDMINSTER, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that MAT2203, its or...